Quetiapine for the treatment of alcoholism: Scientific rationale and review of the literature

Drug and Alcohol Review

Volumn 29, Issue 5, 2010, Pages 568-575

  Ray, Lara A ^a   Heydari, Andia ^a   Zorick, Todd ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alcoholism; Comorbidity; Craving; Quetiapine; Sleep

Indexed keywords

DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; QUETIAPINE;

AFFECT; ALCOHOLISM; ANXIETY; DRUG EFFECT; HUMAN; MENTAL DISEASE; PATHOPHYSIOLOGY; PSYCHIATRIC DIAGNOSIS; REVIEW; SLEEP DISORDER; WITHDRAWAL SYNDROME;

AFFECT; ALCOHOLISM; ANTIPSYCHOTIC AGENTS; ANXIETY; DIAGNOSIS, DUAL (PSYCHIATRY); DIBENZOTHIAZEPINES; HUMANS; MENTAL DISORDERS; SLEEP DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77957914085     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/j.1465-3362.2010.00185.x     Document Type: Review

References (74)

1. Dawson DA, Grant BF, Stinson FS, Chou PS, Huang B, Ruan WJ. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction 2005;100:281-92.
2. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004;74:223-34.
3. Harwood H. Updating estimates of economic costs of alcohol abuse in the United States: estimates, updated methods, and data. Bathesda, MD: NIAAA, 2000.
4. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-18.
5. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993;270:2207-12.
6. Miller WR, Walters ST, Bennett ME. How effective is alcoholism treatment in the United States? J Stud Alcohol 2001;62:211-20.
7. Fuller RK, Hiller-Sturmhofel S. Alcoholism treatment in the United States. An overview. Alcohol Res Health 1999;23:69-77.
8. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986;256:1449-55.
9. De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 2005;19:517-37.
10. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004;28:51-63.
11. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295:2003-17.
12. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49:881-7.
13. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-80.
14. Litten RZ, Allen J, Fertig J. Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. Alcohol Clin Exp Res 1996;20:859-76.
15. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999;156:1758-64.
16. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000;35:587-93.
17. Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001;10:258-68.
18. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25:1634-47.
19. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001;96:1565-73.
20. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001;345:1734-9.
21. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 2000; 22:493-503.
22. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003;28:1546-52.
23. Anton RF, Oroszi G, O'Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008;65:135-44.
24. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 2007;64:1069-77.
25. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000;284:963-71.
26. Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res 2000;24:737-42.
27. Johnson BA, O'Malley SS, Ciraulo DA, et al. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcoholdependent subjects. J Clin Psychopharmacol 2003;23:281-93.
28. Miranda R, Jr, MacKillop J, Monti PM, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 2008;32:489-97.
29. Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulveda I. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol 2004;24:532-5.
30. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 2004;29:452-7.
31. Lindberg N, Tani P, Takala P, et al. Increased deep sleep in a medication-free, detoxified female offender with schizophrenia, alcoholism and a history of attempted homicide: effect of concomitant administration of quetiapine and citalopram. Crim Behav Ment Health 2006;16:60-6.
32. Croissant B, Klein O, Gehrlein L, et al. Quetiapine in relapse prevention in alcoholics suffering from craving and affective symptoms: a case series. Eur Psychiatry 2006; 21:570-3.
33. Potvin S, Stip E, Lipp O, et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006; 22:1277-85.
34. Kampman KM, Pettinati HM, Lynch KG, et al. A doubleblind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol 2007;27:344-51.
35. Babor TF, Caetano R. Subtypes of substance dependence and abuse: implications for diagnostic classification and empirical research. Addiction 2006;101 (Suppl 1):104-10.
36. Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M, Sarchiapone M, Janiri L. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 2008;23: 417-24.
37. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20:389-409.
38. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-72.
39. Hommer DW. Functional imaging of craving. Alcohol Res Health 1999;23:187-96.
40. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238-46.
41. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002;159:1642-52.
42. Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 2002;13:355-66.
43. Davidson D, Palfai T, Bird C, Swift R. Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 1999;23:195-203.
44. Marlatt GA, Gordon JR. Relapse prevention. New York: Guilford, 1985.
45. Tiffany ST. A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes. Psychol Rev 1990;97:147-68.
46. Monti PM, Rohsenow DJ, Rubonis AV, et al. Alcohol cue reactivity: effects of detoxification and extended exposure. J Stud Alcohol 1993;54:235-45.
47. Monti PM, Rohsenow DJ, Rubonis AV, et al. Cue exposure with coping skills treatment for male alcoholics: a preliminary investigation. J Consult Clin Psychol 1993;61:1011-19.
48. Ray LA, Meskew-Stacer S, Hutchison KE. The relationship between prospective self-rating of alcohol sensitivity and craving and experimental results from two alcohol challenge studies. J Stud Alcohol Drugs 2007;68:379-84.
49. Hutchison KE, Ray L, Sandman E, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 2006;31:1310-17.
50. Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 1999;23:1289-95.
51. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994;151:1463-7.
52. Drobes DJ, Anton RF, Thomas SE, Voronin K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 2004;28:1362-70.
53. Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM. Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res 1993;17:140-6.
54. Earleywine M. Confirming the factor structure of the anticipated biphasic alcohol effects scale. Alcohol Clin Exp Res 1994;18:861-6.
55. Erblich J, Earleywine M. Distraction does not impair memory during intoxication: support for the attention-allocation model. J Stud Alcohol 1995;56:444-8.
56. Fox HC, Bergquist KL, Hong KI, Sinha R. Stress-induced and alcohol cue-induced craving in recently abstinent alcohol-dependent individuals. Alcohol Clin Exp Res 2007; 31:395-403.
57. Brower KJ. Insomnia, alcoholism and relapse. Sleep Med Rev 2003;7:523-39.
58. Arnedt JT, Conroy D, Rutt J, Aloia MS, Brower KJ, Armitage R. An open trial of cognitive-behavioral treatment for insomnia comorbid with alcohol dependence. Sleep Med 2007;8:176-80.
59. Brower KJ, Aldrich MS, Robinson EA, Zucker RA, Greden JF. Insomnia, self-medication, and relapse to alcoholism. Am J Psychiatry 2001;158:399-404.
60. Conroy DA, Todd Arnedt J, Brower KJ, et al. Perception of sleep in recovering alcohol-dependent patients with insomnia: relationship with future drinking. Alcohol Clin Exp Res 2006;30:1992-9.
61. DeVane CL, Liston HL. An explanation of the second-dose effect in pharmacokinetics and its meaning for clinical psychopharmacology. Psychopharmacol Bull 2001;35:42-52.
62. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40:509-22.
63. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008;11:999-1029.
64. Rowe DL. Off-label prescription of quetiapine in psychiatric disorders. Expert Rev Neurother 2007;7:841-52.
65. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-25.
66. Miller del D, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193:279-88.
67. Sernyak MJ, Rosenheck RA. Antipsychotic use in the treatment of outpatients with schizophrenia in theVA from fiscal years 1999-2006. Psychiatr Serv 2008;59:567-9.
68. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68 (Suppl 1):20-7.
69. Hanley MJ, Kenna GA. Quetiapine: treatment for substance abuse and drug of abuse. Am J Health Syst Pharm 2008;65:611-18.
70. Reeves RR, Brister JC. Additional evidence of the abuse potential of quetiapine. South Med J 2007;100:834-6.
71. Pierre JM, Shnayder I, Wirshing DA, Wirshing WC. Intranasal quetiapine abuse. Am J Psychiatry 2004;161:1718.
72. Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse. Am J Psychiatry 2005;162:1755-6.
73. Waters BM, Joshi KG. Intravenous quetiapine-cocaine use ('Q-ball'). Am J Psychiatry 2007;164:173-4.
74. Keltner NL, Vance DE. Biological perspectives incarcerated care and quetiapine abuse. Perspect Psychiatr Care 2008; 44:202-6.